James Schuster1, Rose K Lai1, Lawrence D Recht1, David A Reardon1, Nina A Paleologos1, Morris D Groves1, Maciej M Mrugala1, Randy Jensen1, Joachim M Baehring1, Andrew Sloan1, Gary E Archer1, Darell D Bigner1, Scott Cruickshank1, Jennifer A Green1, Tibor Keler1, Thomas A Davis1, Amy B Heimberger1, John H Sampson1. 1. Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania (J.S.); The Neurological Institute of Columbia University, New York, New York (R.K.L.); Stanford Cancer Center, Stanford, California (L.D.R.); Duke University Medical Center, Durham, North Carolina (D.A.R., G.E.A., D.D.B., J.H.S.); Evanston Northwestern Healthcare, Evanston, Illinois (N.A.P.); University of Texas M.D. Anderson Cancer Center, Houston, Texas (M.D.G.); University of Washington School of Medicine, Seattle, Washington (M.M.M.); Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah (R.J.); Yale University School of Medicine, New Haven, Connecticut (J.M.B); University Hospital-Case Medical Center & Case Comprehensive Cancer Center, Cleveland, Ohio (A.S.); Scott Cruickshank & Associates, Inc., Santa Barbara, C alifornia (S.C.); Celldex Therapeutics, Inc., Hampton, New Jersey (J.A.G., T.K., T.A.D.); University of Texas M.D. Anderson Cancer Center, Houston, Texas (A.B.H.).
Abstract
BACKGROUND: The epidermal growth factor receptor variant III deletion mutation, EGFRvIII, is expressed in ∼30% of primary glioblastoma and linked to poor long-term survival. Rindopepimut consists of the unique EGFRvIII peptide sequence conjugated to keyhole limpet hemocyanin. In previous phase II trials (ACTIVATE/ACT II), rindopepimut was well tolerated with robust EGFRvIII-specific immune responses and promising progression-free and overall survival. This multicenter, single-arm phase II clinical trial (ACT III) was performed to confirm these results. METHODS:Rindopepimut and standard adjuvant temozolomide chemotherapy were administered to 65 patients with newly diagnosed EGFRvIII-expressing (EGFRvIII+) glioblastoma after gross total resection and chemoradiation. RESULTS:Progression-free survival at 5.5 months (∼8.5 mo from diagnosis) was 66%. Relative to study entry, median overall survival was 21.8 months, and 36-month overall survival was 26%. Extended rindopepimut vaccination (up to 3.5+ years) was well tolerated. Grades 1-2 injection site reactions were frequent. Anti-EGFRvIII antibody titers increased ≥4-fold in 85% of patients, and increased with duration of treatment. EGFRvIII was eliminated in 4/6 (67%) tumor samples obtained after >3 months of therapy. CONCLUSIONS: This study confirms, in a multicenter setting, the preliminary results seen in previous phase II trials of rindopepimut. A pivotal, double-blind, randomized, phase III trial ("ACT IV") is under way.
RCT Entities:
BACKGROUND: The epidermal growth factor receptor variant III deletion mutation, EGFRvIII, is expressed in ∼30% of primary glioblastoma and linked to poor long-term survival. Rindopepimut consists of the unique EGFRvIII peptide sequence conjugated to keyhole limpet hemocyanin. In previous phase II trials (ACTIVATE/ACT II), rindopepimut was well tolerated with robust EGFRvIII-specific immune responses and promising progression-free and overall survival. This multicenter, single-arm phase II clinical trial (ACT III) was performed to confirm these results. METHODS: Rindopepimut and standard adjuvant temozolomide chemotherapy were administered to 65 patients with newly diagnosed EGFRvIII-expressing (EGFRvIII+) glioblastoma after gross total resection and chemoradiation. RESULTS: Progression-free survival at 5.5 months (∼8.5 mo from diagnosis) was 66%. Relative to study entry, median overall survival was 21.8 months, and 36-month overall survival was 26%. Extended rindopepimut vaccination (up to 3.5+ years) was well tolerated. Grades 1-2 injection site reactions were frequent. Anti-EGFRvIII antibody titers increased ≥4-fold in 85% of patients, and increased with duration of treatment. EGFRvIII was eliminated in 4/6 (67%) tumor samples obtained after >3 months of therapy. CONCLUSIONS: This study confirms, in a multicenter setting, the preliminary results seen in previous phase II trials of rindopepimut. A pivotal, double-blind, randomized, phase III trial ("ACT IV") is under way.
Authors: P A Humphrey; A J Wong; B Vogelstein; M R Zalutsky; G N Fuller; G E Archer; H S Friedman; M M Kwatra; S H Bigner; D D Bigner Journal: Proc Natl Acad Sci U S A Date: 1990-06 Impact factor: 11.205
Authors: H S Huang; M Nagane; C K Klingbeil; H Lin; R Nishikawa; X D Ji; C M Huang; G N Gill; H S Wiley; W K Cavenee Journal: J Biol Chem Date: 1997-01-31 Impact factor: 5.157
Authors: Amy B Heimberger; Roman Hlatky; Dima Suki; David Yang; Jeff Weinberg; Mark Gilbert; Raymond Sawaya; Kenneth Aldape Journal: Clin Cancer Res Date: 2005-02-15 Impact factor: 12.531
Authors: Amy B Heimberger; Laura E Crotty; Gary E Archer; Kenneth R Hess; Carol J Wikstrand; Allan H Friedman; Henry S Friedman; Darell D Bigner; John H Sampson Journal: Clin Cancer Res Date: 2003-09-15 Impact factor: 12.531
Authors: Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: Khalid Al-Nedawi; Brian Meehan; Johann Micallef; Vladimir Lhotak; Linda May; Abhijit Guha; Janusz Rak Journal: Nat Cell Biol Date: 2008-04-20 Impact factor: 28.824
Authors: Christopher E Pelloski; Karla V Ballman; Alfred F Furth; Li Zhang; E Lin; Erik P Sulman; Krishna Bhat; J Matthew McDonald; W K Alfred Yung; Howard Colman; Shiao Y Woo; Amy B Heimberger; Dima Suki; Michael D Prados; Susan M Chang; Fred G Barker; Jan C Buckner; C David James; Kenneth Aldape Journal: J Clin Oncol Date: 2007-06-01 Impact factor: 44.544
Authors: Hai Yan; D Williams Parsons; Genglin Jin; Roger McLendon; B Ahmed Rasheed; Weishi Yuan; Ivan Kos; Ines Batinic-Haberle; Siân Jones; Gregory J Riggins; Henry Friedman; Allan Friedman; David Reardon; James Herndon; Kenneth W Kinzler; Victor E Velculescu; Bert Vogelstein; Darell D Bigner Journal: N Engl J Med Date: 2009-02-19 Impact factor: 176.079
Authors: Michael D Prados; Sara A Byron; Nhan L Tran; Joanna J Phillips; Annette M Molinaro; Keith L Ligon; Patrick Y Wen; John G Kuhn; Ingo K Mellinghoff; John F de Groot; Howard Colman; Timothy F Cloughesy; Susan M Chang; Timothy C Ryken; Waibhav D Tembe; Jeffrey A Kiefer; Michael E Berens; David W Craig; John D Carpten; Jeffrey M Trent Journal: Neuro Oncol Date: 2015-05-01 Impact factor: 12.300
Authors: Donald M O'Rourke; MacLean P Nasrallah; Arati Desai; Jan J Melenhorst; Keith Mansfield; Jennifer J D Morrissette; Maria Martinez-Lage; Steven Brem; Eileen Maloney; Angela Shen; Randi Isaacs; Suyash Mohan; Gabriela Plesa; Simon F Lacey; Jean-Marc Navenot; Zhaohui Zheng; Bruce L Levine; Hideho Okada; Carl H June; Jennifer L Brogdon; Marcela V Maus Journal: Sci Transl Med Date: 2017-07-19 Impact factor: 17.956
Authors: Daniel Dubinski; Johannes Wölfer; Martin Hasselblatt; Tilman Schneider-Hohendorf; Ulrich Bogdahn; Walter Stummer; Heinz Wiendl; Oliver M Grauer Journal: Neuro Oncol Date: 2015-11-17 Impact factor: 12.300